Intelligence Feed event · Equity · 2026-10-07

    Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout

    Question

    Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout

    Direct answer

    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present Licaminlimab at the Eyecelerator @ AAO 2026 conference on October 8. Licaminlimab is an investigational topical anti-TNF alpha agent developed for TNFR1-mediated dry eye disease. The presentation precedes the anticipated year-end topline readout for the registrational PREDICT-1 clinical trial, representing a major upcoming regulatory and commercial catalyst for the company's ophthalmology pipeline.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/oculis-to-present-licaminlimab-at-eyecelerator-ahead-of-predict-1-readout-17fa5b

    EQUITY
    Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present Licaminlimab at the Eyecelerator @ AAO 2026 conference on October 8. Licaminlimab is an investigational topical anti-TNF alpha agent developed for TNFR1-mediated dry eye disease. The presentation precedes the anticipated year-end topline readout for the registrational PREDICT-1 clinical trial, representing a major upcoming regulatory and commercial catalyst for the company's ophthalmology pipeline.
    OCS
    Impact
    57
    OCT 7
    SIG
    88%
    OCS
    Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present Licaminlimab at the Eyecelerator @ AAO 2026 conference on October 8. Licaminlimab is an investigational topical anti-TNF alpha agent developed for TNFR1-mediated dry eye disease. The presentation precedes the anticipated year-end topline readout for the registrational PREDICT-1 clinical trial, representing a major upcoming regulatory and commercial catalyst for the company's ophthalmology pipeline.
    → Clinical progress presentation for Licaminlimab de-risks Oculis pipeline value ahead of PREDICT-1 Phase 3 topline binary data by year-end.
    Impact
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present Licaminlimab at the Eyecelerator @ AAO 2026 conference on October 8. Licaminlimab is an investigational topical anti-TNF alpha agent developed for TNFR1-mediated dry eye disease. The presentation precedes the anticipated year-end topline readout for the registrational PREDICT-1 clinical trial, representing a major upcoming regulatory and commercial catalyst for the company's ophthalmology pipeline.
    Affected
    OCS
    Transmission
    Clinical progress presentation for Licaminlimab de-risks Oculis pipeline value ahead of PREDICT-1 Phase 3 topline binary data by year-end.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSbiotech pipeline valuation de-risking ahead of clinical trial readoutUp1-3mOculis presenting Licaminlimab at Eyecelerator on Oct 8 with PREDICT-1 topline readout expected around year-end.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month